FDA Approves Sotorasib With Panitumumab for KRAS G12C-Mutated Colorectal Cancer

On January 16, US the Food and Drug Administration (FDA) approved sotorasib with panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer, as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. 

For more information read the FDA announcement and the Amgen press release.

Posted on 1/17/2025